Clinical trial

Adjunctive Effects of Psilocybin and a Formulation of Buprenorphine

University of Wisconsin, MadisonRecruitingPhase 1Started Jan 13, 202110 enrolledUnited StatesNCT04161066

Abstract

Primary Aim: In participants with OUD, to characterize adverse events associated with adding two psilocybin doses to a stable buprenorphine-naloxone formulation. Secondary Aim: To evaluate the effect of psilocybin treatment on the effectiveness of a buprenorphine-naloxone maintenance therapy. Secondary Aim: To evaluate the effect of concurrent buprenorphine-naloxone use on the effects of psilocybin therapy. Descriptive Aim: To describe any changes in self-efficacy, quality of life, pain.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

PsilocybinAddiction

Keywords

BuprenorphineNaloxoneBuprenorphine-NaloxonePsilocybin-Assisted TherapyOpioidSubstance Use DisorderPsychedelicOpioid Use Disorder

View on registry

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.

Related research

PreprintPsilocybin

Confirmatory factor analysis of Mystical Experience in Freediving as a recreative way to higher efficiency in sport performance and planet saving and money making

Mitina O, Mirsaidov M, Molchanova N +1

Europe PMC2020

ArticlePsilocybin

Pharmacotherapy to Prevent Alcohol Relapse in Alcohol-Associated Liver Disease.

Zhang W, Hwang SY, Luther J

Europe PMC2025

ArticlePsilocybin

Psychedelic substitution: altered substance use patterns following psychedelic use in a global survey.

Glynos NG, Aday JS, Kruger D +3

Europe PMC2024